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Abstract
Background: A role for Epstein Barr virus (EBV) in multiple sclerosis (MS) has been postulated. Previous systematic reviews
found higher prevalences of anti-EBV antibodies in MS patients compared to controls, but many studies have since been
published, and there is a need to apply more rigorous systematic review methods.
Methodology/Principal Findings:We examined the link between EBV and MS by conducting a systematic review and meta-
analysis of case-control and cohort studies that examined the prevalence of anti-EBV antibodies in the serum of cases and
controls. We searched Medline and Embase databases from 1960 to 2012, with no language restriction. The Mantel-
Haenszel odds ratios (OR) for anti-EBV antibodies sero-positivity were calculated, and meta-analysis conducted. Quality
assessment was performed using a modified version of the Newcastle Ottawa scale. Thirty-nine studies were included.
Quality assessment found most studies reported acceptable selection and comparability of cases and controls. However the
majority had poor reporting of ascertainment of exposure. Most studies found a higher sero-prevalence of anti-EBNA IgG
and anti-VCA IgG in cases compared to controls. The results for anti-EA IgG were mixed with only half the studies finding a
higher sero-prevalence in cases. The meta-analysis showed a significant OR for sero-positivity to anti-EBNA IgG and anti-VCA
IgG in MS cases (4.5 [95% confidence interval (CI) 3.3 to 6.6, p,0.00001] and 4.5 [95% CI 2.8 to 7.2, p,0.00001] respectively).
However, funnel plot examination suggested publication bias for the reporting of the anti-EBNA IgG. No significant
difference in the OR for sero-positivity to anti-EA IgG was found (1.4 [95% CI 0.9 to 2.1, p = 0.09]).
Conclusion/Significance: These findings support previous systematic reviews, however publication bias cannot be
excluded. The methodological conduct of studies could be improved, particularly with regard to reporting and conduct of
laboratory analyses.
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Introduction
Multiple Sclerosis (MS) is a complex, chronic, inflammatory,
neurological disease that affects the central nervous system [1].
Worldwide there are 2.5 million people with MS [2] and in the
United Kingdom (UK) alone the number is estimated to be
100,000 people [3]. The public health burden is huge and related
to both direct medical care and loss of productivity from disability
that the disease causes. It was estimated that the overall cost of MS
in the UK was £1.5 billion in 1999 and a recent study estimated
the mean annual cost to be over £30,000 pounds per patient [4].
The aetiology of the disease is still not well understood. Both
genetic and environmental factors play roles in the development of
the disease [5]. Environmental factors have been an area of intense
research lately, particularly into infectious agents that could be
linked to MS and many bacterial and viral agents have been
studied [6]
Of all infectious agents, Epstein Barr virus (EBV) has been most
strongly associated with MS [7].
The odds ratio (OR) for MS patients to be EBV sero-negative
was found to be 0.06 in a review by Ascherio and Munger [7], and
in a more recent meta-analysis combining results from 22 studies
the OR was found to be 0.18 [8]. It also appears that the titres of
anti-EBV antibodies are significantly higher among sero-positive
MS cases when compared with sero-positive controls. Prospective
studies suggest this increase in anti EBV antibodies is apparent
from 5 to 20 years before the onset of MS [9].
The most recent systematic review that updated the association
between MS and sero-positivity for different anti-EBV antibodies
was that of Santiago et al. from 2010 [10]. Literature search terms
were limited and only publications in English and Spanish were
included [10]. This increases the likelihood of publication bias
affecting the results. Many studies have been published more
recently, which could help to estimate the association more fully.
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Therefore, we undertook a systematic review and meta-analysis
with a wider, more comprehensive search strategy, with no
language restriction and including both older and more recently
published studies.
Materials and Methods
The methods of the systematic review followed a pre-specified
protocol developed by the authors.
Search strategy
Medline and Embase were electronically searched using a
comprehensive list of MeSH and Emtree headings and text words
that were informed by previous reviews and from search tools in
Ovid Medline and Embase (Appendix S1). The search was
conducted for articles published from 1960 to March week one,
2012, with no language restriction.
For a study to be included in the review, it had to be a case-
control or a cohort study, recruited patients with MS diagnosis
(confirmed or probable) and controls with no MS diagnosis
(healthy or non-healthy). Participants could be from any age group
and studies measured serum anti-EBV IgG antibodies (using any
method) in both cases and controls. We had few exclusion criteria
in order to be as generalisable as possible. Exclusion criteria were
non-human studies, very small studies with less than 20 cases or 20
controls and studies that only measured anti-EBV IgM (indicating
recent infection).
Titles and abstracts for inclusion were reviewed by one author.
A second author reviewed part of the search results (140 out of
1056 reports) and a kappa statistic for the degree of agreement
between the two reviewers was calculated and was high at 0.76.
Full texts of potentially relevant articles were then screened by one
author and uncertainties discussed with a second author.
Reference lists from included studies were hand searched to
identify any further related studies. Where extra data were
required, the author of the article was contacted to obtain further
information. Relevant data from each study were initially
extracted independently by two authors (23 out of 39 studies).
After sufficient agreement was reached, data were extracted by
one author and checked by a second author.
Quality assessment
The quality assessment of included studies was based on the
Newcastle-Ottawa assessment scale (NOS) [11]. We modified the
exposure assessment criteria so that the subcategories would be
applicable to serological studies. We added a two stars for blinding
of blood sample analysts, one star for conducting the analysis in a
clinical laboratory (away from investigators), one star for
mentioning explicit laboratory cut-offs for sero-positivity, and
one star for reporting the presence or absence of missing data.
Data analysis
The Mantel-Haenzsel odds ratio (OR) of sero-positivity to EBV
was calculated for each anti-EBV antibody (anti-Epstein-Barr
Nuclear Antigen 1 (anti-EBNA1) or EBNA complex, anti-Viral
Capsid Antigen (anti-VCA) and anti-Early Antigen (anti-EA)), and
for sero-negativity to EBV using Review Manager Version 5.1
[12]. The ORs were combined in a meta-analysis for each anti-
EBV antibody and for overall EBV sero-negativity using a pre-
specified more conservative random effects model (anticipating
study heterogeneity) with a 95% confidence interval (CI) for all
analyses. I2 was used to assess heterogeneity between studies [13].
In meta-analyses with sufficient number of studies, a funnel plot
[13] was inspected visually to assess for publication bias.
We conducted subgroup and sensitivity analysis testing of the
meta-analyses in Review Manager version 5.1 to compare the OR
of sero-positivity for the three anti-EBV antibodies in the following
categories:
1. Paediatric versus (vs.) adult studies. We considered studies with
median participant’s age of 20 or less as paediatric,
2. Studies above median latitude vs. those below median latitude.
All studies were assigned to latitude according to area of
recruitment of participants. If the area of recruitment was not
clear, studies were assigned to latitude according to the address
of the lead author,
3. Studies controlling for age vs. those that did not,
4. Studies controlling for gender vs. those that did not,
5. Studies using McDonald[14]/Poser criteria[15] for MS
diagnosis vs. those that did not or criteria used were not clear,
6. Studies that included only cases with confirmed MS diagnosis
vs. those that included confirmed and probable cases,
7. Studies that used Immunofluorescence assays (IFA) vs. those
which used Enzyme-linked immunosorbent assays (ELISA),
8. Studies with overall quality assessment scores above the median
in the modified NOS scale compared to those scoring below
the median.
To minimise the effect of multiple comparisons, we used 99%
CI for all subgroup and sensitivity analyses.
Results
After removing duplicate reports, the search through Medline
and Embase yielded 1056 reports (Figure 1, adapted from Moher,
et al., 2009 [16]). We then excluded case reports, non-human
studies, studies with no serological studies performed or with
unclear serological results, studies and conference abstracts with
no obtainable full reports, retracted studies, studies with an
updated version, studies using inappropriate cases (non-MS) or
with unclear case definition and studies with cases or controls less
than 20. Total number of included studies was 39[17–55]
(Table 1). We received extra unpublished data form five studies
included in the review [28,29,35,49,52].
The characteristics of participants in the included studies are
summarised in Table 1. All studies included were either case-
control studies or nested case-control in cohort studies. There were
5020 cases and 5844 controls. The median sample size of cases
and controls was 108 and 82, respectively. Around half of the
studies specified using McDonald or Poser criteria for MS
diagnosis (21 out of 39 studies) with cases including confirmed,
probable and clinically isolated syndrome (CIS) patients. Controls
included healthy and non-healthy participants (patients with
neurological and non-neurological diseases), with the majority of
studies recruiting healthy control samples (28 out of 39). Most
studies recruited hospital controls (24 out of 39). The rest either
recruited samples from the community or did not state the source.
There were seven paediatric studies [17,19,31,37,41,45,54] and 32
adult studies.
Anti-EBNA IgG
There were 30 studies that tested for anti-EBNA IgG (anti-
EBNA1 or EBNA complex IgG) sero-prevalence (for details of
type of anti-EBNA IgG measured in each study, see Table 1). We
divided the study by Sundstrom et al. [50] into two, retrospective
and prospective, making the total number of studies 31. The
MS and EBV Sero-Epidemiology
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median sero-positivity in the 31 studies in cases was 98%
compared to 88% in controls.
The meta-analysis generated an overall OR of 4.47 (95% CI
3.26–6.11, p,0.0001) (Figure 2). There was considerable hetero-
geneity between studies with I2 = 43% (p= 0.007). Removing the
two studies [18,35] which measured EBNA complex had no effect
on the overall result (OR 4.56, 95% CI 3.27–6.37). Another seven
studies [17,23,31,32,39,43,46] did not clearly state which form of
EBNA was measured; if these are also removed the result is little
changed (OR 4.30, 95% CI 2.90–6.39).
The funnel plot revealed an asymmetrical distribution of studies
around the line of identity, indicating the possibility of publication
bias (Figure 3).
Anti-VCA IgG
There were 24 studies that tested for anti-VCA IgG sero-
prevalence. After dividing the study Sundstrom et al. [50] into two
the total number became 25. The median anti-VCA IgG sero-
positivity in the 25 studies was higher in cases than controls (99%
compared to 92%).
The meta-analysis generated an OR of 4.51 (95% CI 2.84 to
7.16, p,0.00001) (Figure 4). Again there was considerable
heterogeneity between studies with I2 = 59% (p= 0.0001). A
funnel plot revealed a slightly less asymmetrical distribution of
studies than for anti-EBNA IgG (Figure 5).
Anti-EA IgG
There were 14 studies that tested for anti-EA IgG sero-
prevalence. The median sero-positivities in the 14 studies in cases
and controls were similar (18% and 16% respectively).
The meta-analysis generated an overall OR of 1.4 (95% CI 0.9
to 2.1, p = 0.09) (Figure 6 - Note: the study Wagner, et al.,
(2000)[56] in Figure 6 is an older version of the study Wandinger,
et al., (2000)[53]). The heterogeneity higher than that of the
previous two analyses with I2 = 70% (p,0.0001). The funnel plot
revealed a more symmetrical distribution of studies, suggesting
publication bias is less likely (Figure 7).
Anti-EBV IgG sero-negativity
We considered sero-negativity data as adequate if the authors
mentioned explicitly that cases and controls were negative for all
anti-EBV anti-bodies (EBNA, VCA and EA) or mentioned that
they were EBV negative without specifying which anti-EBV
antibody they were negative for. Based on this, only seven studies
Figure 1. Studies identification in search strategy. Adopted from PRISMA 2009 Flow Diagram[16] (Moher, et al., 2009)*.
doi:10.1371/journal.pone.0061110.g001
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provided data for the analysis [17,30,33,38,39,41,53]. The median
prevalence of anti-EBV IgG sero-negativity in the seven studies
was lower in cases than controls (0.7% compared to 10%).
The meta-analysis generated an overall OR of 0.13 (95% CI
0.05 to 0.33, p,0.0001) (Figure 8). Heterogeneity between studies
was again significant I2 = 56% (p= 0.03). Due to the small number
of studies in the analysis, a funnel plot was not used to assess the
risk of publication bias.
Subgroup analysis
To examine the effect of different factors on the overall OR for
anti-EBV sero-positivity, we conducted eight subgroup analyses
(Tables 2, 3, 4, 5, 6, 7, 8, and 9), five of which were post hoc
(Tables 4, 5, 7, 8, and 9). Of note is that none of the subgroup
differences reached statistical significance although there are some
trends seen in the results.
Paediatric studies had a slightly higher OR than adult studies
for anti-EBNA and anti-VCA sero-positivity (above 5 compared to
4 or below) (Table 2). Subgroup analysis by the latitude of studies
did not reveal a clear trend, with a higher OR for anti-EBNA sero-
positivity in studies above the median latitude (45.37 north) while
the OR for anti-VCA was higher in studies below the median
latitude (Table 3).
Studies that matched for age or sex had higher ORs for all anti-
EBV IgG sero-positivities compared to those that did not (Tables 4
and 5). The ORs for all anti-EBV IgG sero-positivities was similar
in studies that stated using McDonald/Poser criteria, compared to
those that did not specify, or used different criteria (Table 6).
However, when we compared studies with confirmed MS cases to
those with confirmed and probable/CIS cases, the OR was higher
in the former group for anti-EBNA and VCA sero-positivity
(Table 7). Studies that used IFA as method of detection of anti-
EBV IgG, had double the OR for anti-VCA and EA sero-
positivity, but not for anti-EBNA, compared to studies that used
ELISA (Table 8).
Quality assessment
In our modified NOS scale the maximum score that could be
achieved by a study was 12 stars. The majority of studies scored
below half this with an overall median of five. The highest scoring
studies were by Ascherio, et al., Levin, et al., and Ponsonby, et al.,
with score of 11 stars [18,33,42] (Table 10).
Figure 2. Forest plot of the Odds Ratio for anti-EBNA sero-positivity.
doi:10.1371/journal.pone.0061110.g002
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Figure 3. Funnel plot for studies testing for anti-EBNA IgG sero-positivity.
doi:10.1371/journal.pone.0061110.g003
Figure 4. Forest plot of the Odds Ratio for anti-VCA IgG sero-positivity.
doi:10.1371/journal.pone.0061110.g004
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For selection criteria, the majority of studies had adequate
definitions of cases and controls. However only a quarter of the
studies recruited an obviously representative or a consecutive
sample of cases, and only six studies recruited adequate
community controls without an obvious source of bias. For the
comparability criteria, 28 out of 39 studies matched cases and
controls for at least one factor, with half of the studies matching for
age and at least one additional factor. For the exposure criteria,
only a quarter of studies reported blinding sample analysts, with
three studies reporting conducting the serology in clinical
laboratory (distant from the investigators). Half of the studies
reported explicitly serological cut off values with only eight studies
reporting whether there were missing data (related to participants’
recruitment and withdrawal/analytical failures).
To examine the effect of the quality of studies on the OR for
anti-EBV sero-positivity, we compared studies with a quality
assessment score above the median (a score of five) with studies
scoring at or below the median in a post hoc analysis. The OR of
Figure 5. Funnel plot of studies testing for anti-VCA IgG sero-positivity.
doi:10.1371/journal.pone.0061110.g005
Figure 6. Forest plot of the Odds Ratio for anti-EA IgG sero-positivity. Note: the study Wagner, et al., (2000)[56] in Figure 6 is an older
version of the study Wandinger, et al., (2000)[53].
doi:10.1371/journal.pone.0061110.g006
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sero-positivity was higher for all anti-EBV IgG outcomes in studies
scoring above the median (Table 9), although there was no
statistically significant difference.
Discussion
This review has again found an association between EBV sero-
positivity, based on anti-EBNA and anti-VCA IgG testing. We also
found no evidence for a difference in sero-prevalence of anti-EA
IgG, indicative of recent infection.
There was considerable between study heterogeneity, and we
examined different factors that might have been influential.
Although none of the subgroup analyses reached statistical
significance, several trends emerged. There was a slightly higher
OR in paediatric studies compared to adult studies. This might be
connected to higher overall exposure of adults to EBV infection
than paediatric controls. However, Pakpoor et al. [8] found the
OR of sero-negativity to anti-EBV antibodies to be similar in
paediatric and adult MS cases. This discrepancy in the findings
may be due to chance or the small number of paediatric studies
included (only three) by Pakpoor, et al. [8]
We did not find a difference in combined OR between studies
using more recent criteria (McDonald/Poser) compared to older
criteria or failure to report criteria (which may simply reflect lack
of reporting). The post hoc analysis according to the diagnosis status
of MS participants revealed a higher combined OR in studies
recruiting only confirmed vs. confirmed and probable/CIS
patients for exposure to anti-EBNA and VCA IgG. This finding
is plausible as unconfirmed MS patients are more likely to be
misclassified and therefore have a lower prevalence of EBV
exposure than true MS patients.
Studies matching for age and/or sex were found to have higher
ORs for anti-EBNA and VCA IgG sero-positivity. Other
important confounders are geographical location and socio-
economic status. We could not test for the effect of controlling
for these factors because few studies explicitly mentioned
controlling for them. Comparison of studies according to their
latitude did not reveal a trend. In some studies the exact area of
Figure 7. Funnel plot of studies testing for anti-EA IgG sero-positivity.
doi:10.1371/journal.pone.0061110.g007
Figure 8. Forest plot of the Odds ratio for anti-EBV IgG sero-negativity.
doi:10.1371/journal.pone.0061110.g008
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Table 2. Combined OR in paediatric vs. adult studies.
Specificity of
Antibody Paediatric studies Adult Studies
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 5.48 (3.29–9.14)/7 studies 4.12 (2.39–7.10)/24 studies 0.32
VCA 5.72 (2.82–11.58)/6 studies 3.79 (1.62–8.82)/19 studies 0.34
EA 0.72 (0.1–5.29)/3 studies 1.51 (0.86–2.66)/11 studies 0.36
Note: P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t002
Table 3. Combined OR in studies below median latitude vs. above the median.
Specificity of
Antibody
Studies below median latitude (29.25–45.
37) North
Studies above median latitude (45.39–63.49)
North
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 3.81(1.86–7.83)/13 studies 6.32 (3.91–10.20)/16 studies 0.13
VCA 6.16 (3.67–10.35)/12 studies 2.99 (0.74–12.12)/10 studies 0.21
EA 1.45 (0.35, 6.08)/5 studies 1.33 (0.72, 2.46)/8 studies 0.88
Note: P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t003
Table 4. Combined OR in studies matching for age vs. not matching for age.
Specificity of
Antibody Studies Matching for Age Studies not Matching for age
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 5.80 (3.13, 10.75)/20 studies 3.23 (2.09, 4.97)/11 studies 0.04
VCA 5.26 (2.20, 12.54)/16 studies 3.67 (1.69, 7.98)/9 studies 0.43
EA 1.52 (0.86, 2.69)/11 studies 0.77 (0.21, 2.79)/3 studies 0.21
Note: post hoc analyses. P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t004
Table 5. Combined OR in studies matching for sex vs. not matching for sex.
Specificity of
Antibody Studies Matching for sex Studies not Matching for sex
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 5.52 (2.75, 11.06)/16 studies 3.64 (2.38, 5.56)/15 studies 0.19
VCA 6.79 (2.93, 15.70)/13 studies 3.03 (1.51, 6.09)/12 studies 0.06
EA 1.62 (0.83, 3.16)/8 studies 1.04 (0.40, 2.73)/6 studies 0.33
Note: post hoc analyses. P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t005
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Table 6. Combined OR in studies using McDonlad/Poser criteria vs. other/criteria not specified.
Specificity of
Antibody Studies using McDonlad/Poser Criteria
Studies using other criteria/criteria not
specified
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 4.14 (2.14, 7.99)/15 studies 4.86 (3.11, 7.58)/16 studies 0.6
VCA 4.42 (1.58, 12.38)/10 studies 4.58 (2.05, 10.20)/15 studies 0.9
EA 1.44 (0.66, 3.14)/7 studies 1.33 (0.69, 2.55)/8 studies 0.84
Note: P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t006
Table 7. Combined OR in studies with confirmed MS cases vs. Confirmed and probable cases.
Specificity of
Antibody Confirmed MS Confirmed and probable MS
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 5.25 (3.37, 8.16)/18 studies 3.41 (1.69, 6.87)/13 studies 0.18
VCA 6.23 (2.96, 13.10)/14 studies 3.12 (1.30, 7.51)/11 studies 0.12
EA 1.33 (0.62, 2.83)/8 studies 1.53 (0.50, 4.66)/5 studies 0.07
Note: post hoc analyses. P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t007
Table 8. Combined OR in studies using IFA vs. ELISA.
Specificity of
Antibody IFA ELISA
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 3.95 (2.04, 7.64)/8 studies 4.24 (2.46, 7.32)/21 studies 0.83
VCA 6.71 (2.40, 18.76)/12 studies 3.38 (1.50, 7.65)/13 studies 0.18
EA 2.24 (1.11, 4.52)/4 studies 1.08 (0.61, 1.92)/10 studies 0.04
Note: post hoc analyses. P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t008
Table 9. Combined OR in studies with quality assessment score of 6 (median) or above vs. below 6.
Specificity of AntibodyQuality 6 and above Quality less than 6
Difference significance (P
value)
OR (99% CI) OR (99% CI)
EBNA 5.24 (2.68, 10.23)/14 studies 3.59 (2.27, 5.67)/17 studies 0.23
VCA 5.21 (2.40, 11.29)/12 studies 3.89 (1.52, 9.97)/13 studies 0.54
EA 1.57 (0.86, 2.86)/8 studies 1.17 (0.40, 3.43)/6 studies 0.54
Note: post hoc analyses. P value is significant at or below 0.01.
doi:10.1371/journal.pone.0061110.t009
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recruitment was not mentioned and an estimate had to be used. A
recent study by Disanto et al. [57] found that higher latitude was
associated with higher prevalence of EBV exposure, independent
from MS status.
Comparing the OR in studies that used IFA to detect anti-EBV
antibodies vs. those that used ELISA, revealed that the former had
double the OR for anti-VCA and anti-EA IgG sero-positivity but
similar results for anti-EBNA. These results are consistent with the
analysis by Pakpoor et al. [8] who found that studies that used IFA
generated a much lower OR for sero-negativity of anti-EBV
antibodies in MS cases compared studies which used ELISA.
Table 10. Quality assessment of included studies.
Study ID Selection Comparability Exposure Total
S1 S2 S3 S4 C1 C2 E1 a E1 b E2 E3 E4
Alotaibi 2004[17] * – – * * – ** * – * * 8
Ascherio 2001[18] * * * * * * ** – * * * 11
Banwell 2007[19] * – – * * – ** * – * * 8
Bray 1983[20] – * – – * * – – – * – 4
Buljevac 2005[21] * – – * * – – – * * * 6
Comabella 2010[22] – * – * * – – – – * – 4
Ferrante 1987[23] – – – – – * – – – * – 2
Gutierrez 2002[24] – – – – – – – – – * – 1
Haahr 2004[25] – – – * * * – – – * – 4
Ingram 2010[26] – – – * – – – – * * – 3
Jafari 2010[27] * – – * – – – – – * – 3
Jaquiery 2010[28] – * – – – – – – – * – 2
Jilek 2008[29] * – – – – – – – * * – 3
Khaki 2011[30] * – – * * * – – * * – 6
Lalive 2011[31] – – – * – – – – – * – 2
Larsen 1985[32] – – – * * * ** – * * – 7
Levin 2010[33] * * * * * * ** – * * * 11
Lindsey 2010[34] – – – – * * – – * * – 4
Lucas 2011[35] * * * * * * – – * * * 9
Martyn 1993[36] – – – * * – – – – * – 3
Mowry 2011[37] – – – * – – ** – * * – 5
Munch 1998[38] – – – * * * – – – * – 4
Myhr 1998[39] * * – * * * – – – * – 6
Nociti 2010[40] * – – * – – – – * * – 4
Pohl 2006[41] * – – * * * ** – * * – 8
Ponsonby 2005[42] * * * * * * ** * * * – 11
Riverol 2007[43] * – – * * * – – * * * 7
Sellner 2010[44] * – – * * – – – * * – 5
Selter 2010[45] – * – * – – – – * * – 4
Shirodaria 1987[46] – – – * * * – – * * – 5
Sumaya 1980[47] * – – * – – – – – * – 3
Sumaya 1985[48] * – – * * * – – – * – 5
Sundqvist 2012[49] * * * * * * – – * * – 8
Sundstro¨m 2004[50] * * * * * * ** – – * * 10
Villegas 2011[51] * – – * – – – – – * – 3
Villoslada 2003[52] * – – * * * – – * * – 6
Wandinger 2000[53] * * – * * * – – * * – 7
Waubant 2011[54] * – – * * * ** – * * – 8
Zivadinov 2006[55] * * – * * * – – – * – 6
Abbreviations: C1: Matching for age, C2: Matching for additional factor, E1 a: Blinding of sample analysts, E1 b: Conducted analysis in clinical laboratory, E2: Explicit
serology cut-off values reported, E3: Same serology method used for cases and controls, E4: Missing data reported, S1: Adequate definition of cases, S2: Consecutive or
obviously representative cases, S3: Adequate community controls, S4: Adequate definition of controls.
doi:10.1371/journal.pone.0061110.t010
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Other factors that may contribute to the differences in estimates
of ORs are the selection and source of cases and controls. Few
studies clearly described the method of selection of cases
(consecutive, random, all, or a percentage of the eligible cases).
Ideally, the community would be the best source for controls [58].
Only six studies were deemed to have appropriate community
controls [18,33,35,42,49,50]. There were seven studies which
recruited blood/bone marrow donors, which we considered
inappropriate community controls, as such donors are selected
for non-health risk behaviour. Looking at the results of six studies
which recruited a control sample of patients with other neurolog-
ical diseases (OND) [23,24,27,28,37,40] and comparing them to
seven studies which recruited only seemingly healthy hospital
controls [17,19,26,38,39,41,51], we observed that, among the
former group, only two out of the six studies found a statistically
significant higher anti-EBV IgG sero-prevalence in cases [27,37]
compared to all seven studies in the latter group.
At least half of the studies scored poorly in our modified NOS
scale for quality assessment. This may partly relate to poor
reporting rather than poor conduct. This highlights the impor-
tance of following a standardised method for reporting to ensure
that all relevant information is reported and to facilitate
interpretation and validity assessment of studies. One such method
is the STROBE statement (Strengthening the Reporting of
Observational Studies in Epidemiology), which was developed to
address standardised reporting of observational studies [59]. The
NOS scale presently does not allow for uncertainty in quality
assessment. Having the option to choose unclear in the criteria for
assessment as used by the tool for assessing risk of bias in
randomised controlled trials developed by the Cochrane Collab-
oration [13] would be helpful. Despite the limitation of the NOS
quality assessment scale, we did find that studies with better
methodological conduct are more likely to find stronger associa-
tions between EBV exposure and MS.
One major strength of this review is a more thorough search
strategy with no language restriction. Despite this, we only found a
single published study from areas other than Europe, North
America and Australia (Asian study–Khaki et al. [30]). This
emphasises the need for future studies to test the association of
EBV with MS in other areas of the world with very different,
generally lower prevalences of MS.
For consistent handling of data, we analysed the crude data in
our meta-analyses, as very few studies provided adjusted odds
ratios [18,19,54], nor adjusted for the same factors. We did not
separate out prospective data presented in three studies [18,33,50]
from the main meta-analyses, but removing these data has no
effect on the results (data available from the authors). The funnel
plot for anti-EBNA IgG sero-positivity revealed the possibility of
publication bias, but this is unlikely to negate the main association.
Our review includes more than double the number of studies
included in the most recently published systematic review by
Santiago et al. [10]; the results are similar but more precise.
Although Santiago et al. [10] did assess the quality of included
studies, they did not examine the potential for publication bias,
and used more limited quality assessment. We found a similar
result for sero-negativity to the systematic review by Pakpoor et al.
[8] who did not undertake any quality assessment of the studies.
The possible role for EBV as a cause of MS provides the
potential to prevent or reduce MS through vaccination against
EBV [60]. Further research related to EBV and MS could focus
on further characterising the risk of MS based on titres of anti-
EBV antibodies. Although there have been studies which
examined titre levels and MS risk [18,50,61,62], the data have
not yet been combined in a systematic review. Better character-
isation of anti-EBV antibodies titres and the associated risk of MS
could potentially identify high risk groups and help in prevention
or management.
In conclusion, there is strong epidemiological evidence that MS
patients have higher sero-prevalence of anti-EBV antibodies
compared to controls.
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